The neutralizing antibody SAR156597 for IL-4 and IL-13, which directly induce CCL17, reduced the CCL17 levels in the plasma and exhibited significant improvement in the skin scores and a trend toward improved respiratory function in a phase II study of the multiorgan fibrosing disease scleroderma [26]. Here, CCL17 is linked to scleroderma.